We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · February 09, 2021

Efficacy of Osimertinib + Bevacizumab vs Osimertinib in EGFR-Mutated NSCLC Previously Treated With EGFR-TKI

JAMA Oncology

 

Additional Info

JAMA Oncology
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial
JAMA Oncol 2021 Jan 07;[EPub Ahead of Print], H Akamatsu, Y Toi, H Hayashi, D Fujimoto, M Tachihara, N Furuya, S Otani, J Shimizu, N Katakami, K Azuma, N Miura, K Nishino, S Hara, S Teraoka, S Morita, K Nakagawa, N Yamamoto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading